Xiaojing Lai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaojing Lai has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Andre Dekker
Department of Radiation Oncology (Maastro), GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Centre
2 shared publicationsHangjie Ying
Zhejiang Cancer Institute, The Cancer Hospital of The University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang 310022, P.R. China
2 shared publicationsLeonard Wee
Department of Radiation Oncology (Maastro), GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Centre
2 shared publicationsMin Fang
Department of Radiation Oncology, Institute of Basic Medicine and Cancer, Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, P.R. China
2 shared publications- Min Fang
Department of Thoracic Radiotherapy, Key Laboratory of Radiation Oncology of Zhejiang Province, Zhejiang Cancer Hospital, Hangzhou, China
2 shared publications Qing Gu
Department of Thoracic Radiotherapy, Key Laboratory of Radiation Oncology of Zhejiang Province, Zhejiang Cancer Hospital, Hangzhou, China
2 shared publications
Latest Publications
- Open Access
- 7 April 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1793039
Adapting federated radiomics models for radiation pneumonitis prediction in patients receiving thoracic radiotherapy with immunotherapy
Background and purpose: Radiation pneumonitis (RP) is one of the major dose-limiting toxicities of thoracic radiotherapy. Although multiple studies have attempted to predict RP, robust multicenter model development is often hindered by privacy regulations and data-transfer constraints, and many existing models are primarily derived from radiotherapy-alone populations, limiting applicability to contemporary regimens that incorporate immunotherapy. Therefore, this study aimed to develop an RP prediction model within a federated learning framework, incorporating sequential transfer learning strategies to enable separate risk assessment for radiotherapy patients with and without immunotherapy. Methods: Multicenter cohorts of lung cancer patients treated with definitive thoracic radiotherapy with or without immunotherapy were retrospectively collected and stratified by immunotherapy exposure. Radiomics features were extracted from whole-lung regions on pretreatment planning CT scans to construct RP prediction models. A federated learning framework was first applied to non-immunotherapy patients to learn common features of radiation pneumonitis without sharing raw data. The pretrained federated model was then sequentially transferred to immunotherapy treatment cohorts, with targeted fine-tuning to adapt to treatment specific RP patterns. Model performance was evaluated through internal validation and independent external validation, with SHAP analysis exploring feature importance differences across treatment settings. Results: A total of 610 patients were included from five multicenter cohorts. Using patients without immunotherapy for model development, the federated baseline model showed stable discrimination in external validation across non-immunotherapy cohorts (AUC = 0.77). When this baseline model was directly applied to the immunotherapy cohort without adaptation, performance dropped markedly (AUC = 0.43). After fine-tuning on immunotherapy data, the immunotherapy-adapted model achieved improved performance within the immunotherapy cohort (AUC = 0.76) and remained robust in an independent external immunotherapy validation cohort (AUC = 0.75). Feature attribution analysis showed a shift in model coefficients between immunotherapy-treated and non-immunotherapy patients. Conclusion: A federated modeling framework with treatment adaptation improves RP risk prediction across heterogeneous treatment settings under multicenter data constraints, particularly in immunotherapy-treated patients.
- 7 April 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1793039
Open AccessAdapting federated radiomics models for radiation pneumonitis prediction in patients receiving thoracic radiotherapy with immunotherapy
Background and purpose: Radiation pneumonitis (RP) is one of the major dose-limiting toxicities of thoracic radiotherapy. Although multiple studies have attempted to predict RP, robust multicenter model development is often hindered by privacy regulations and data-transfer constraints, and many existing models are primarily derived from radiotherapy-alone populations, limiting applicability to contemporary regimens that incorporate immunotherapy. Therefore, this study aimed to develop an RP prediction model within a federated learning framework, incorporating sequential transfer learning strategies to enable separate risk assessment for radiotherapy patients with and without immunotherapy. Methods: Multicenter cohorts of lung cancer patients treated with definitive thoracic radiotherapy with or without immunotherapy were retrospectively collected and stratified by immunotherapy exposure. Radiomics features were extracted from whole-lung regions on pretreatment planning CT scans to construct RP prediction models. A federated learning framework was first applied to non-immunotherapy patients to learn common features of radiation pneumonitis without sharing raw data. The pretrained federated model was then sequentially transferred to immunotherapy treatment cohorts, with targeted fine-tuning to adapt to treatment specific RP patterns. Model performance was evaluated through internal validation and independent external validation, with SHAP analysis exploring feature importance differences across treatment settings. Results: A total of 610 patients were included from five multicenter cohorts. Using patients without immunotherapy for model development, the federated baseline model showed stable discrimination in external validation across non-immunotherapy cohorts (AUC = 0.77). When this baseline model was directly applied to the immunotherapy cohort without adaptation, performance dropped markedly (AUC = 0.43). After fine-tuning on immunotherapy data, the immunotherapy-adapted model achieved improved performance within the immunotherapy cohort (AUC = 0.76) and remained robust in an independent external immunotherapy validation cohort (AUC = 0.75). Feature attribution analysis showed a shift in model coefficients between immunotherapy-treated and non-immunotherapy patients. Conclusion: A federated modeling framework with treatment adaptation improves RP risk prediction across heterogeneous treatment settings under multicenter data constraints, particularly in immunotherapy-treated patients.
- Open Access
- 3 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1787518
Cross-dataset adaptation of voxel-level deep radiomics for predicting survival in inoperable locally advanced NSCLC treated with immunotherapy
Background and purpose: Predicting overall survival (OS) for inoperable locally advanced non-small cell lung cancer (LA-NSCLC) treated with immune checkpoint inhibitors remains challenging due to heterogeneous clinical response. Furthermore, the application of advanced deep learning is hindered by limited immunotherapy datasets. This study aimed to develop a novel prognostic framework by integrating voxel-level deep radiomics derived from pretreatment imaging with a knowledge transfer strategy to accurately predict OS. Materials and methods: A total of 526 patients were respectively identified. A non-immunotherapy dataset from the RTOG 0617 clinical trial was used to pre-train a Vision-Mamba deep learning model to learn tumor characteristics within manually delineated tumor regions. Voxel-level radiomics feature maps were generated within tumors and integrated with CT images for dual-input co-training. Using the same dual-input, a cross-dataset transfer learning strategy was then used to adapt the pre-trained models to the immunotherapy context by fine-tuning. The model’s performance was evaluated using the concordance index (C-index), time-dependent area under the receiver operating characteristic curve, Kaplan-Meier survival analysis, calibration curves, and decision curve analysis. Additionally, Gradient-weighted Class Activation Mapping (Grad-CAM) was employed to suggest a possible interpretation of the model’s decision logic. Results: The proposed model demonstrated robust generalization ability. In the independent immunotherapy testing dataset, the model achieved a C-index of 0.73 (95% CI:0.63-0.82). The time-dependent AUCs for predicting 1-year and 2-year OS were 0.73 and 0.70, respectively. Calibration curves showed good agreement between predicted and observed survival probability. Stratification analysis showed distinct survival differences, with the high-risk group exhibiting significantly poorer OS compared to low-risk group (P<0.001). Conclusion: We developed a voxel-level deep radiomics framework that bridges the data gap in immunotherapy research through fine-tuning on a limited immunotherapy dataset, and subsequent validation on an independent immunotherapy testing dataset, demonstrating robust generalizability.
- 3 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1787518
Open AccessCross-dataset adaptation of voxel-level deep radiomics for predicting survival in inoperable locally advanced NSCLC treated with immunotherapy
Background and purpose: Predicting overall survival (OS) for inoperable locally advanced non-small cell lung cancer (LA-NSCLC) treated with immune checkpoint inhibitors remains challenging due to heterogeneous clinical response. Furthermore, the application of advanced deep learning is hindered by limited immunotherapy datasets. This study aimed to develop a novel prognostic framework by integrating voxel-level deep radiomics derived from pretreatment imaging with a knowledge transfer strategy to accurately predict OS. Materials and methods: A total of 526 patients were respectively identified. A non-immunotherapy dataset from the RTOG 0617 clinical trial was used to pre-train a Vision-Mamba deep learning model to learn tumor characteristics within manually delineated tumor regions. Voxel-level radiomics feature maps were generated within tumors and integrated with CT images for dual-input co-training. Using the same dual-input, a cross-dataset transfer learning strategy was then used to adapt the pre-trained models to the immunotherapy context by fine-tuning. The model’s performance was evaluated using the concordance index (C-index), time-dependent area under the receiver operating characteristic curve, Kaplan-Meier survival analysis, calibration curves, and decision curve analysis. Additionally, Gradient-weighted Class Activation Mapping (Grad-CAM) was employed to suggest a possible interpretation of the model’s decision logic. Results: The proposed model demonstrated robust generalization ability. In the independent immunotherapy testing dataset, the model achieved a C-index of 0.73 (95% CI:0.63-0.82). The time-dependent AUCs for predicting 1-year and 2-year OS were 0.73 and 0.70, respectively. Calibration curves showed good agreement between predicted and observed survival probability. Stratification analysis showed distinct survival differences, with the high-risk group exhibiting significantly poorer OS compared to low-risk group (P<0.001). Conclusion: We developed a voxel-level deep radiomics framework that bridges the data gap in immunotherapy research through fine-tuning on a limited immunotherapy dataset, and subsequent validation on an independent immunotherapy testing dataset, demonstrating robust generalizability.
- 16 August 2023
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 40 (5) , 423-429
Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real world
The immunotherapy combined chemotherapy has been the standard treatment strategy for extensive-stage small lung cancer (ES-SCLC). The CREST trial reported consolidative thoracic radiotherapy (cTRT) improved overall survival (OS) for ES-SCLC with intrathoracic residual after chemotherapy. In this study, patients with ES-SCLC who received immunotherapy were assigned to receive either TRT or no TRT. TRT significantly improved progression-free survival (PFS), local recurrence-free survival (LRFS) and OS with well tolerated toxicity. Further sub-cohort analysis, TRT significantly improved LRFS in patients with oligo-metastasis and without liver metastasis.
- 16 August 2023
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 40 (5) , 423-429
Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real world
The immunotherapy combined chemotherapy has been the standard treatment strategy for extensive-stage small lung cancer (ES-SCLC). The CREST trial reported consolidative thoracic radiotherapy (cTRT) improved overall survival (OS) for ES-SCLC with intrathoracic residual after chemotherapy. In this study, patients with ES-SCLC who received immunotherapy were assigned to receive either TRT or no TRT. TRT significantly improved progression-free survival (PFS), local recurrence-free survival (LRFS) and OS with well tolerated toxicity. Further sub-cohort analysis, TRT significantly improved LRFS in patients with oligo-metastasis and without liver metastasis.
- Open Access
- 3 August 2023
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 26 (3) , 1-13
Triple‑negative breast cancer cells that survive ionizing radiation exhibit an Axl‑dependent aggressive radioresistant phenotype
This study aimed to investigate the aggressive behavior of triple‑negative breast cancer (TNBC) cells that had survived ionizing radiation and explore the potential targets of TNBC combination treatment. Consistent with the previous literature, Axl was highly expressed in TNBC and closely associated with the degree of malignancy based on immunohistochemical staining. Using a gradient irradiation method, the ionizing radiation‑resistant mouse TNBC cell line 4T‑1/IRR was established. It was found that Axl expression was upregulated in 4T‑1/IRR cells. After irradiation by X‑ray, the cell viability and colony formation ability of 4T‑1/IRR cells were significantly increased when compared with the 4T‑1 cells. Combined radiotherapy with Axl inhibition by treatment with R428 and small interfering RNA lentivirus targeting Axl infection significantly reduced cell viability, colony formation ability, DNA double‑stranded break repair, and the invasive and migratory ability of 4T‑1/IRR cells. In vivo, the small animal radiation research platform was applied to precisely administer radiotherapy of the tumor‑bearing mice. R428 treatment combined with 6 Gy X‑ray significantly inhibited the growth of 4T‑1/IRR cells‑derived xenograft tumors in the BALB/c mouse. The results of western blotting showed that the critical molecular mechanism involved in the radioresistance of TNBC cells was the PI3K/Akt/mTOR signaling pathway induced by Axl activation. Thus, it is hypothesized that targeted Axl therapy combined with radiotherapy may have significant potential for the treatment of TNBC.
- 3 August 2023
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 26 (3) , 1-13
Open AccessTriple‑negative breast cancer cells that survive ionizing radiation exhibit an Axl‑dependent aggressive radioresistant phenotype
This study aimed to investigate the aggressive behavior of triple‑negative breast cancer (TNBC) cells that had survived ionizing radiation and explore the potential targets of TNBC combination treatment. Consistent with the previous literature, Axl was highly expressed in TNBC and closely associated with the degree of malignancy based on immunohistochemical staining. Using a gradient irradiation method, the ionizing radiation‑resistant mouse TNBC cell line 4T‑1/IRR was established. It was found that Axl expression was upregulated in 4T‑1/IRR cells. After irradiation by X‑ray, the cell viability and colony formation ability of 4T‑1/IRR cells were significantly increased when compared with the 4T‑1 cells. Combined radiotherapy with Axl inhibition by treatment with R428 and small interfering RNA lentivirus targeting Axl infection significantly reduced cell viability, colony formation ability, DNA double‑stranded break repair, and the invasive and migratory ability of 4T‑1/IRR cells. In vivo, the small animal radiation research platform was applied to precisely administer radiotherapy of the tumor‑bearing mice. R428 treatment combined with 6 Gy X‑ray significantly inhibited the growth of 4T‑1/IRR cells‑derived xenograft tumors in the BALB/c mouse. The results of western blotting showed that the critical molecular mechanism involved in the radioresistance of TNBC cells was the PI3K/Akt/mTOR signaling pathway induced by Axl activation. Thus, it is hypothesized that targeted Axl therapy combined with radiotherapy may have significant potential for the treatment of TNBC.
- Open Access
- 14 February 2023
- Published by Spandidos Publications in Oncology Letters
- Vol. 25 (3) , 1-11
Impact of the immune molecular profile of the tumor microenvironment on the prognosis of NSCLC
The present study aimed to clarify the association between macrophages, tumor neo‑vessels and programmed cell death‑ligand 1 (PD‑L1) in the tumor microenvironment and the clinicopathological features of patients with non‑small cell lung cancer (NSCLC), and to explore the prognostic factors of stromal features in NSCLC. To determine this, tissue microarrays containing samples of 92 patients with NSCLC were studied using immunohistochemistry and immunofluorescence. The quantitative data demonstrated that in tumor islets, the number of CD68+ and CD206+ tumor‑associated macrophages (TAMs) was 8‑348 (median, 131) and 2‑220 (median, 52), respectively (P+ and CD206+ TAMs was 23‑412 (median, 169) and 7‑358 (median, 81), respectively (P+ TAMs, and they were significantly correlated (P+ TAMs in tumor stroma and islets and a high density of CD206+ TAMs and PD‑L1 in tumor stroma were associated with worse prognosis (both P+ TAMs in tumor islets and stroma, or CD206+ TAMs in tumor islets and stroma. To the best of our knowledge, the present study was the first to provide a multi‑component combined prognostic survival analysis of different types of macrophages in different regions with tumor neo‑vessels and PD‑L1, which demonstrated the importance of macrophages in tumor stroma.
- 14 February 2023
- Published by Spandidos Publications in Oncology Letters
- Vol. 25 (3) , 1-11
Open AccessImpact of the immune molecular profile of the tumor microenvironment on the prognosis of NSCLC
The present study aimed to clarify the association between macrophages, tumor neo‑vessels and programmed cell death‑ligand 1 (PD‑L1) in the tumor microenvironment and the clinicopathological features of patients with non‑small cell lung cancer (NSCLC), and to explore the prognostic factors of stromal features in NSCLC. To determine this, tissue microarrays containing samples of 92 patients with NSCLC were studied using immunohistochemistry and immunofluorescence. The quantitative data demonstrated that in tumor islets, the number of CD68+ and CD206+ tumor‑associated macrophages (TAMs) was 8‑348 (median, 131) and 2‑220 (median, 52), respectively (P+ and CD206+ TAMs was 23‑412 (median, 169) and 7‑358 (median, 81), respectively (P+ TAMs, and they were significantly correlated (P+ TAMs in tumor stroma and islets and a high density of CD206+ TAMs and PD‑L1 in tumor stroma were associated with worse prognosis (both P+ TAMs in tumor islets and stroma, or CD206+ TAMs in tumor islets and stroma. To the best of our knowledge, the present study was the first to provide a multi‑component combined prognostic survival analysis of different types of macrophages in different regions with tumor neo‑vessels and PD‑L1, which demonstrated the importance of macrophages in tumor stroma.
- Open Access
- 12 January 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 1055610
Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non–small cell lung cancer in real world
Objectives: The combination of immunotherapy and chemotherapy has shown great efficacy in stage IV non–small cell lung cancer (NSCLC) and is now widely used in clinical treatment strategy. This study retrospectively analyzed the efficacy and safety of neoadjuvant immunotherapy plus chemotherapy for resectable NSCLC in real world.Methods: We retrospectively analyzed patients with NSCLC who received neoadjuvant immunotherapy plus chemotherapy and underwent complete tumor resection in Zhejiang Cancer Hospital between January 2019 and January 2021. Tumor staging was based on the eighth TNM classification system of the American Joint Committee on Cancer staging criteria. The safety and toxicity (including operative and postoperative complications) and the efficacy [including objective response rate (ORR), disease control rate (DCR), tumor major pathological remission (MPR), and pathological complete response (pCR)] were evaluated.Results: In total, 368 patients with NSCLC were administered with neoadjuvant immunotherapy. Of them, 211 patients were included in this retrospective study. Most patients had stage II–III disease, with 75 (35.5%) and 88 (41.7%) patients diagnosed with clinical stages IIB and IIIA, respectively. A total of 206 patients (97.6%) received at least two doses of neoadjuvant immunotherapy plus chemotherapy. In addition, 121 patients (57.3%) have achieved MPR, and 80 patients (37.9%) have achieved pCR, with ORR at 69.2% and DCR at 97.7%. Treatment-related adverse events occurred in 46.4% of patients, and the incidence rate of grade 3 or 4 treatment-related adverse events was 13.3% (13/98). Moreover, adverse events of any grade of surgical complication occurred in 15.6% of patients. One-year disease-free survival was 80.6% (170/211).Conclusions: Neoadjuvant immunotherapy plus chemotherapy has significant efficacy with a high pCR and tolerable adverse effects for patients with resectable stage II–III NSCLC in real world.
- 12 January 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 1055610
Open AccessEfficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non–small cell lung cancer in real world
Objectives: The combination of immunotherapy and chemotherapy has shown great efficacy in stage IV non–small cell lung cancer (NSCLC) and is now widely used in clinical treatment strategy. This study retrospectively analyzed the efficacy and safety of neoadjuvant immunotherapy plus chemotherapy for resectable NSCLC in real world.Methods: We retrospectively analyzed patients with NSCLC who received neoadjuvant immunotherapy plus chemotherapy and underwent complete tumor resection in Zhejiang Cancer Hospital between January 2019 and January 2021. Tumor staging was based on the eighth TNM classification system of the American Joint Committee on Cancer staging criteria. The safety and toxicity (including operative and postoperative complications) and the efficacy [including objective response rate (ORR), disease control rate (DCR), tumor major pathological remission (MPR), and pathological complete response (pCR)] were evaluated.Results: In total, 368 patients with NSCLC were administered with neoadjuvant immunotherapy. Of them, 211 patients were included in this retrospective study. Most patients had stage II–III disease, with 75 (35.5%) and 88 (41.7%) patients diagnosed with clinical stages IIB and IIIA, respectively. A total of 206 patients (97.6%) received at least two doses of neoadjuvant immunotherapy plus chemotherapy. In addition, 121 patients (57.3%) have achieved MPR, and 80 patients (37.9%) have achieved pCR, with ORR at 69.2% and DCR at 97.7%. Treatment-related adverse events occurred in 46.4% of patients, and the incidence rate of grade 3 or 4 treatment-related adverse events was 13.3% (13/98). Moreover, adverse events of any grade of surgical complication occurred in 15.6% of patients. One-year disease-free survival was 80.6% (170/211).Conclusions: Neoadjuvant immunotherapy plus chemotherapy has significant efficacy with a high pCR and tolerable adverse effects for patients with resectable stage II–III NSCLC in real world.